[Role of anaerobic bacteria in community-acquired respiratory pathology].
Dubreuil
L
L
Hôpital Dron, Tourcolng.
D019980:Amoxicillin-Potassium Clavulanate Combination / Q000494:pharmacology / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use; D001421:Bacteria, Anaerobic / Q000187:drug effects / Q000302:isolation & purification; D001424:Bacterial Infections / Q000175:diagnosis / Q000188:drug therapy; D017714:Community-Acquired Infections; D004359:Drug Therapy, Combination / Q000494:pharmacology / Q000627:therapeutic use; D016724:Empyema, Pleural / Q000188:drug therapy / Q000382:microbiology; D006801:Humans; D008169:Lung Abscess / Q000188:drug therapy / Q000382:microbiology; D008173:Lung Diseases, Obstructive / Q000188:drug therapy / Q000382:microbiology; D008826:Microbial Sensitivity Tests; D010998:Pleurisy / Q000188:drug therapy / Q000382:microbiology; D018410:Pneumonia, Bacterial / Q000188:drug therapy / Q000382:microbiology; D012141:Respiratory Tract Infections / Q000188:drug therapy / Q000382:microbiology*
D000900:Anti-Bacterial Agents; D019980:Amoxicillin-Potassium Clavulanate Combination